WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H556010
CAS#: 1366302-52-4 (free base)
Description: Gozetotide, also known as PSMA-11, DKFZ-PSMA-11, HBED-CC-PSMA or Psma-hbed-CC, is a ligand to make gallium Ga 68-labeled PSMA-11, which has potential use as a tracer for PSMA-expressing tumors during positron emission tomography (PET). Upon intravenous administration of gallium Ga 68-labeled PSMA-11, the Glu-urea-Lys(Ahx) moiety targets and binds to PSMA-expressing tumor cells. Upon internalization, PSMA-expressing tumor cells can be detected during PET imaging. PSMA, a tumor-associated antigen and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells
Hodoodo Cat#: H556010
Name: PSMA-11 free base
CAS#: 1366302-52-4 (free base)
Chemical Formula: C44H62N6O17
Exact Mass: 946.42
Molecular Weight: 947.005
Elemental Analysis: C, 55.81; H, 6.60; N, 8.87; O, 28.72
Related CAS #: 2412149-32-5 (TFA) 1366302-52-4 (free base) PSMA-11 HCl
Synonym: DKFZ-PSMA-11; Psma-hbed-CC; PSMA-11; PSMA11; PSMA 11; HBED-CC-PSMA; PSMA-11 TFA; Psma-hbed-CC; gozetotide;
IUPAC/Chemical Name: (3S,7S)-22-(3-(((2-((5-(2-Carboxyethyl)-2-hydroxybenzyl)(carboxymethyl)amino)ethyl)(carboxymethyl)amino)methyl)-4-hydroxyphenyl)-5,13,20-trioxo-4,6,12,19-tetraazadocosane-1,3,7-tricarboxylic acid
InChi Key: QJUIUFGOTBRHKP-LQJZCPKCSA-N
InChi Code: InChI=1S/C44H62N6O17/c51-34-13-8-28(22-30(34)24-49(26-40(59)60)20-21-50(27-41(61)62)25-31-23-29(9-14-35(31)52)11-16-38(55)56)10-15-37(54)46-18-4-1-2-7-36(53)45-19-5-3-6-32(42(63)64)47-44(67)48-33(43(65)66)12-17-39(57)58/h8-9,13-14,22-23,32-33,51-52H,1-7,10-12,15-21,24-27H2,(H,45,53)(H,46,54)(H,55,56)(H,57,58)(H,59,60)(H,61,62)(H,63,64)(H,65,66)(H2,47,48,67)/t32-,33-/m0/s1
SMILES Code: O=C(O)CC[C@H](NC(N[C@@H](CCCCNC(CCCCCNC(CCC1=CC=C(O)C(CN(CC(O)=O)CCN(CC2=CC(CCC(O)=O)=CC=C2O)CC(O)=O)=C1)=O)=O)C(O)=O)=O)C(O)=O
Appearance: Solid powder
Purity: >97% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | Ga 68 PSMA-11 binds to prostate-specific membrane antigen (PSMA). It binds to cells that express PSMA, including malignant prostate cancer cells, which usually overexpress PSMA. Gallium-68 (Ga 68) is a β+ emitting radionuclide that allows positron emission tomography (PET). |
| In vitro activity: | The procedure was completely automated and provided a high radiochemical yield. It can be performed several times a day, facilitating the clinical demand of this radiopharmaceutical. Reference: Reverchon J, Khayi F, Roger M, Moreau A, Kryza D. Optimization of the radiosynthesis of [68Ga]Ga-PSMA-11 using a Trasis MiniAiO synthesizer: do we need to heat and purify? Nucl Med Commun. 2020 Sep;41(9):977-985. doi: 10.1097/MNM.0000000000001233. PMID: 32796487. |
| In vivo activity: | A total of 635 men were enrolled with a median age of 69 years (range, 44-95 years). On a per-patient basis, PPV was 0.84 (95% CI, 0.75-0.90) by histopathologic validation (primary endpoint, n = 87) and 0.92 (95% CI, 0.88-0.95) by the composite reference standard (n = 217). 68Ga-PSMA-11 PET localized recurrent prostate cancer in 475 of 635 (75%) patients; detection rates significantly increased with prostate-specific antigen (PSA): 38% for |
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| To be determined | 100.0 | 105.60 |
The following data is based on the product molecular weight 947.01 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | Reverchon J, Khayi F, Roger M, Moreau A, Kryza D. Optimization of the radiosynthesis of [68Ga]Ga-PSMA-11 using a Trasis MiniAiO synthesizer: do we need to heat and purify? Nucl Med Commun. 2020 Sep;41(9):977-985. doi: 10.1097/MNM.0000000000001233. PMID: 32796487. |
| In vitro protocol: | Reverchon J, Khayi F, Roger M, Moreau A, Kryza D. Optimization of the radiosynthesis of [68Ga]Ga-PSMA-11 using a Trasis MiniAiO synthesizer: do we need to heat and purify? Nucl Med Commun. 2020 Sep;41(9):977-985. doi: 10.1097/MNM.0000000000001233. PMID: 32796487. |
| In vivo protocol: | Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, Nguyen HG, Reiter RE, Rettig MB, Okamoto S, Emmett L, Zacho HD, Ilhan H, Wetter A, Rischpler C, Schoder H, Burger IA, Gartmann J, Smith R, Small EJ, Slavik R, Carroll PR, Herrmann K, Czernin J, Hope TA. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol. 2019 Jun 1;5(6):856-863. doi: 10.1001/jamaoncol.2019.0096. PMID: 30920593; PMCID: PMC6567829. |
1: Ghezzo S, Mapelli P, Bezzi C, Samanes Gajate AM, Brembilla G, Gotuzzo I, Russo T, Preza E, Cucchiara V, Ahmed N, Neri I, Mongardi S, Freschi M, Briganti A, De Cobelli F, Gianolli L, Scifo P, Picchio M. Role of [68Ga]Ga- PSMA-11 PET radiomics to predict post-surgical ISUP grade in primary prostate cancer. Eur J Nucl Med Mol Imaging. 2023 Mar 18. doi: 10.1007/s00259-023-06187-3. Epub ahead of print. PMID: 36933074.
2: Tang CYL, Lim GKY, Chua WM, Ng CWQ, Koo SX, Goh CX, Thang SP, Zaheer S, Lam WWC, Huang HL. Optimization of Bayesian penalized likelihood reconstruction for 68Ga-prostate-specific membrane antigen-11 PET/computed tomography. Nucl Med Commun. 2023 Mar 15. doi: 10.1097/MNM.0000000000001687. Epub ahead of print. PMID: 36917459.
3: Burgard C, Hoffmann MA, Frei M, Buchholz HG, Khreish F, Marlowe RJ, Schreckenberger M, Ezziddin S, Rosar F. Detection Efficacy of 68Ga- PSMA-11 PET/CT in Biochemical Recurrence of Prostate Cancer with Very Low PSA Levels: A 7-Year, Two-Center "Real-World" Experience. Cancers (Basel). 2023 Feb 21;15(5):1376. doi: 10.3390/cancers15051376. PMID: 36900169; PMCID: PMC10000220.
4: Bauckneht M, Miceli A, Signori A, Albano D, Capitanio S, Piva R, Laudicella R, Franchini A, D'Amico F, Riondato M, Chiola S, Marini C, Fornarini G, Scarale A, Muni A, Bertagna F, Burger IA, Sambuceti G, Morbelli S. Combined forced diuresis and late acquisition on [68Ga]Ga-PSMA-11 PET/CT for biochemical recurrent prostate cancer: a clinical practice-oriented study. Eur Radiol. 2023 Mar 9. doi: 10.1007/s00330-023-09516-0. Epub ahead of print. PMID: 36892650.
5: Donswijk ML, Piek MW, Cheung Z, Wondergem M, Stokkel MPM, de Boer JP, van der Ploeg IMC. Incidence of PSMA PET thyroid incidentaloma depends on analysis method and tracer. Eur Radiol. 2023 Mar 9. doi: 10.1007/s00330-023-09492-5. Epub ahead of print. PMID: 36892644.
6: Chattopadhyay S, Ash S, Mahesh DG, Barua L, Mitra A, Das SS, Singha S, Nayer MA, Madhusmita, Kumar U, Sinha S. Preparation of [68Ga]Ga-Chloride from 68Zn solid target for the synthesis of pharmaceutical grade [68Ga]Ga-PSMA-11 and [68Ga]Ga-DOTA-TATE. Appl Radiat Isot. 2023 May;195:110744. doi: 10.1016/j.apradiso.2023.110744. Epub 2023 Feb 26. PMID: 36867922.
7: Kim M, Seifert R, Fragemann J, Kersting D, Murray J, Jonske F, Pomykala KL, Egger J, Fendler WP, Herrmann K, Kleesiek J. Evaluation of thresholding methods for the quantification of [68Ga]Ga-PSMA-11 PET molecular tumor volume and their effect on survival prediction in patients with advanced prostate cancer undergoing [177Lu]Lu-PSMA-617 radioligand therapy. Eur J Nucl Med Mol Imaging. 2023 Mar 2. doi: 10.1007/s00259-023-06163-x. Epub ahead of print. PMID: 36859618.
8: Muraglia L, Mattana F, Travaini LL, Musi G, Bertani E, Renne G, Pisa E, Ferrari ME, Fumagalli Romario U, De Cobelli O, Fusco N, Ceci F. First Live- Experience Session with PET/CT Specimen Imager: A Pilot Analysis in Prostate Cancer and Neuroendocrine Tumor. Biomedicines. 2023 Feb 20;11(2):645. doi: 10.3390/biomedicines11020645. PMID: 36831181; PMCID: PMC9953571.
9: Vetrone L, Cuzzani G, Mei R, Zanoni L, Bertaccini A, Bianchi L, Castellucci P, Gaudiano C, Cappelli A, Giunchi F, Fanti S. Case report: PSMA PET/CT addresses the correct diagnosis in a patient with metastatic prostate cancer despite negative core biopsies and mpMRI. A diagnostic challenge. Front Oncol. 2023 Feb 7;13:1101221. doi: 10.3389/fonc.2023.1101221. PMID: 36824128; PMCID: PMC9941543.
10: Wang B, Deng Y, Xu Q, Gao J, Shen H, He X, Ding Q, Wang F, Guo H. Exploration of 68Ga-labelled prostate-specific membrane antigen-11 PET/CT parameters for identifying PBRM1 status in primary clear cell renal cell carcinoma. Clin Radiol. 2023 Feb 1:S0009-9260(23)00025-9. doi: 10.1016/j.crad.2023.01.003. Epub ahead of print. PMID: 36805287.
11: Kim MH, Lee K, Oh K, Kim CH, Kil HS, Lee YJ, Lee KC, Chi DY. Evaluation of PSMA target diagnostic PET tracers for therapeutic monitoring of [177Lu]ludotadipep of prostate cancer: Screening of PSMA target efficiency and biodistribution using [18F]DCFPyL and [68Ga]PSMA-11. Biochem Biophys Res Commun. 2023 Apr 9;651:107-113. doi: 10.1016/j.bbrc.2023.02.003. Epub 2023 Feb 11. PMID: 36801611.
12: Liu Y, Niu S, Luan X, Zhang X, Liu J, Zhang J, Wang R, Xu B, Zhang X. Can 18F-PSMA-7Q PET/CT replace prostate biopsy for the diagnosis of prostate cancer?-A single-center retrospective study. Transl Androl Urol. 2023 Jan 30;12(1):83-89. doi: 10.21037/tau-22-813. Epub 2023 Jan 12. PMID: 36760865; PMCID: PMC9906103.
13: Sonni I, Dal Pra A, O'Connell DP, Ells Z, Benz M, Nguyen K, Yoon SM, Deng J, Smith C, Grogan T, Nickols NG, Cao M, Kishan AU, Calais J. PSMA PET/CT-based Atlas for Prostatic Bed Recurrence after Radical Prostatectomy: Clinical Implications for Salvage Radiation Therapy Contouring Guidelines. J Nucl Med. 2023 Feb 9:jnumed.122.265025. doi: 10.2967/jnumed.122.265025. Epub ahead of print. PMID: 36759200.
14: Arslan E, Ergül N, Beyhan E, Erol Fenercioglu Ö, Sahin R, Cin M, Battal Havare S, Can Trabulus FD, Mermut Ö, Akbas S, Fikret Çermik T. The roles of 68 Ga-PSMA PET/CT and 18 F-FDG PET/CT imaging in patients with triple-negative breast cancer and the association of tissue PSMA and claudin 1, 4, and 7 levels with PET findings. Nucl Med Commun. 2023 Apr 1;44(4):284-290. doi: 10.1097/MNM.0000000000001663. Epub 2023 Feb 9. PMID: 36756767.
15: Afshar-Oromieh A, Eiber M, Fendler W, Schmidt M, Rahbar K, Ahmadzadehfar H, Umutlu L, Hadaschik B, Hakenberg OW, Fornara P, Kurth J, Neels O, Wester HJ, Schwaiger M, Kopka K, Haberkorn U, Herrmann K, Krause BJ; Deutsche Gesellschaft für Urologie e. V. (DGU); Deutsche Röntgengesellschaft e. V. (DRG). DGN- Handlungsempfehlung (S1-Leitlinie) – PSMA-Liganden-PET/CT in der Diagnostik des Prostatakarzinoms – Stand: 01/2022 – AWMF-Registernummer: 031-055 [Procedure Guideline for Prostate Cancer Imaging with PSMA-ligand PET/CT]. Nuklearmedizin. 2023 Feb;62(1):5-19. German. doi: 10.1055/a-1984-8167. Epub 2023 Feb 6. PMID: 36746147.
16: Grahovac M, Spielvogel CP, Krajnc D, Ecsedi B, Traub-Weidinger T, Rasul S, Kluge K, Zhao M, Li X, Hacker M, Haug A, Papp L. Machine learning predictive performance evaluation of conventional and fuzzy radiomics in clinical cancer imaging cohorts. Eur J Nucl Med Mol Imaging. 2023 Feb 4. doi: 10.1007/s00259-023-06127-1. Epub ahead of print. PMID: 36738311.
17: Urso L, Rocca GC, Uccelli L, Ippolito C, Bartolomei M. 18 F-Choline Versus 68 Ga-PSMA-11 PET/CT Imaging Comparison in Incidental Clear Cell Renal Cell Carcinoma. Clin Nucl Med. 2023 Apr 1;48(4):e178-e180. doi: 10.1097/RLU.0000000000004515. Epub 2023 Feb 1. PMID: 36728284.
18: Aggarwal P, Kaur K, Sood A, Periasamy K, Nagi S, Mittal BR. Increased PSMA Expression in 177Lu-PSMA-617 Scan in Metastatic Castrate-Resistant Prostate Cancer Patient Treated With PSMA Radioligand Therapy and Enzalutamide: A Potential Game-Changer. Clin Nucl Med. 2023 Jan 12. doi: 10.1097/RLU.0000000000004529. Epub ahead of print. PMID: 36728226.
19: Adediran OA, Lawal IO, Muzahir S, Bhave MA, Friend S, Fielder B, Meisel J, Torres MA, Styblo TM, Graham C, Holbrook A, Kalinsky K, Crowe RJ, Ulaner GA, Schuster DM. A Discordant Pattern of Uptake on 68 Ga-PSMA PET/CT Versus 18 F-Fluciclovine PET/CT in Radiation-Induced Hepatitis : Implications for Early Postradiotherapy Imaging-Based Response Assessment. Clin Nucl Med. 2023 Apr 1;48(4):e202-e203. doi: 10.1097/RLU.0000000000004565. Epub 2023 Jan 14. PMID: 36728139.
20: Riaz S, Priftakis D, Afaq A, Kayani I, Bomanji J. 68 Ga-PSMA-Avid Intranasal Solitary Fibrous Tumor. Clin Nucl Med. 2023 Apr 1;48(4):e184-e185. doi: 10.1097/RLU.0000000000004572. Epub 2023 Jan 20. PMID: 36727873.
